Recent developments include quarterly earnings reports showing losses with revenue exceeding expectations, clinical data releases supporting product efficacy, FDA clearances and label expansion submissions for AYON, and international market launches including China.

• Apyx Medical reported a Q3 2026 net loss but revenue exceeded expectations, reflecting ongoing operational challenges and market traction [N1].
• The company held a Q2 2026 earnings call discussing financial results and business updates [N3].
• Q2 2026 results showed a loss but revenue beat expectations, indicating some commercial progress [N4].
• Positive clinical data was released for Renuvion in cellulite reduction, supporting product efficacy [N6].
• The company expanded FDA clearance for the AYON Body Contouring System, enhancing its market offering [N5].
• Apyx Medical's Q1 2026 earnings transcript detailed operational and financial performance [N8].

The company’s innovative Helium Plasma Technology and integrated AYON platform address a growing demand for comprehensive body contouring solutions, particularly as GLP-1 drug use influences patient needs for skin laxity treatment. FDA clearances and international market entries, including China, expand the addressable market. Cost-saving measures and operational efficiencies have reduced expenses, supporting financial sustainability. Strong patent protection and clinical data support product differentiation and adoption.

Recurring net losses and cash outflows present ongoing financial challenges. The company depends on continued FDA clearances and market acceptance of its products. Supply chain disruptions and inflationary pressures could impact manufacturing and costs. Compliance with financial covenants requires meeting revenue and expense targets, and failure to secure additional financing could constrain operations. Competitive pressures and potential patent infringements pose risks to market share and profitability.

Apyx Medical's competitive advantages include its proprietary Helium Plasma Technology, a broad portfolio of patents and trademarks protecting its innovations, FDA clearances for key products, and a comprehensive product platform (AYON) that integrates multiple body contouring modalities. Its manufacturing capabilities in certified facilities and a global sales and clinical support network further strengthen its market position. The company's focus on innovation, quality, and clinical support creates barriers to entry and supports customer loyalty in the surgical aesthetics market.

• Financial Losses and Liquidity: The company has incurred recurring net losses and cash outflows from operations, with ongoing losses anticipated in the near term. Maintaining liquidity depends on cash reserves, product sales, and potential equity or debt financing, which may not be available on acceptable terms.
• Regulatory and Market Acceptance: Continued FDA clearances and market acceptance of products like AYON and Renuvion are critical. Delays or failures in regulatory approvals or slower adoption could adversely affect business prospects.
• Supply Chain and Cost Pressures: Global supply chain instability and inflationary cost increases may impact raw material availability and pricing, potentially affecting production and financial performance.
• Competitive and Intellectual Property Risks: Competitors may develop similar or non-infringing products, and patent infringement or challenges could erode competitive advantages.

• Apyx Medical Corp is a surgical aesthetics company incorporated in 1982 with principal executive office in Clearwater, Florida.
• The company markets and sells Helium Plasma Platform Technology products including Renuvion®, AYON Body Contouring System™, and J-Plasma® in cosmetic surgery and hospital surgical markets.
• Renuvion and J-Plasma provide controlled heat to tissue for surgical results; AYON is an FDA-cleared, surgeon-designed body contouring system integrating fat removal, contouring, tissue contraction, and electrosurgical capabilities.
• AYON received FDA 510(k) clearance on May 13, 2025, with a soft launch followed by commercial launch in September 2025.
• AYON's features include infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation, volume enhancement, and Renuvion treatment for loose skin.
• The company submitted a 510(k) premarket notification to FDA for AYON label expansion to include power liposuction in October 2025, with clearance anticipated in Q2 2026.
• Renuvion launched in China in July 2025 after receiving market clearance from China's National Medical Products Administration.
• Apyx Medical has a joint venture with a Chinese supplier owning 51% to establish presence in China for manufacturing and sales, commencing operations in Q2 2025.
• The company has 41 US patents, 61 foreign patents, and multiple pending patent applications and trademarks protecting its technology and products.
• Manufacturing occurs primarily in Clearwater, Florida and Sofia, Bulgaria, both ISO13485:2016 certified and FDA regulated.
• The company experienced supply chain delays and inflationary cost impacts but no material backlog or financial impact to date.
• Apyx Medical had 205 full-time employees worldwide as of December 31, 2025, with low voluntary turnover and no collective bargaining agreements.
• The company undertook a cost-saving restructuring in November 2024 reducing US workforce by nearly 25%, eliminating bonuses, and reducing board size and compensation.
• Annual operating expenses were reduced below $40 million in 2025 compared to prior years.
• The company has a credit facility with Perceptive Credit Holdings IV, LP, initially $45 million with amendments reducing revenue and expense covenants, and was in compliance as of December 31, 2025.
• As of September 30, 2026, Apyx Medical had $25.8 million in cash and equivalents, $53.8 million in current assets, $10.9 million in current liabilities, a current ratio of 4.95, and a cash ratio of 6.02.
• The company reported a net loss of $1.785 million and basic EPS of -$0.04 for the quarter ended September 30, 2026.
• The cosmetic surgery market includes surgical, minimally invasive, and nonsurgical procedures, with body contouring growing due to factors including GLP-1 drug use causing loose skin.
• Renuvion is the only FDA-approved device for treating skin laxity post liposuction and may be used without liposuction, potentially expanding the market.
• The company’s sales force and international distributors focus on becoming the sole provider of surgical equipment in cosmetic surgical markets, supported by clinical specialists and marketing.
• Recent news reports cover quarterly earnings losses with revenue exceeding expectations, clinical data releases, FDA clearances, and market expansion efforts.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.